Marinomed Biotech Ag · VIE:MARI
Marinomed Biotech — FY2023 Earnings Presentation
31 slides from Marinomed Biotech's earnings presentation, Apr 16, 2024
Slide 1: Investor presentation Full Year 2023
Investor presentation Full Year 2023 Andreas Grassauer, CEO Eva Prieschl-Grassauer, CSO Pascal Schmidt, CFO Korneuburg, April 16th, 2024
Slide 2: Disclaimer
Disclaimer This presentation (the “Presentation”) was prepared by Marinomed Biotech AG. The information contained in this Presentation has not been independently verified and no representation or warranty expressed or implied is made as to, and no reliance should be placed on, the fairness, accuracy
Slide 3: Agenda
Agenda • Highlights 2023 Andreas Grassauer, CEO • Financials 2023 Pascal Schmidt, CFO • Marinomed therapeutic areas, pipeline, Andreas Grassauer, CEO recent developments and next steps • New Carragelose data Eva Prieschl-Grassauer, CSO • Project status update & outlook Andreas Grassauer, CEO • Finan
Slide 4: Highlights last 12 months
Highlights last 12 months Steady steps towards commercialization of our assets EUR 9.2 m New products Solv4U EIB agreement Carragelose eye 18 months deferral Revenues clearly First long-term drops (preparing for of repayments to EIB above pre-pandemic partnership with SPH launch) and allergy and rea
Slide 5: Agenda
Agenda • Highlights 2023 Andreas Grassauer, CEO • Financials 2023 Pascal Schmidt, CFO • Marinomed therapeutic areas, pipeline, Andreas Grassauer, CEO recent developments and next steps • New Carragelose data Eva Prieschl-Grassauer, CSO • Project status update & outlook Andreas Grassauer, CEO • Finan
Slide 6: Revenue in line with post-pandemic market
Revenue in line with post-pandemic market High customer stock-levels lead to slow order intake Y-o-Y comparison of quarterly revenues (m€) Comments Historical numbers 11.3 9.2 • Revenues expectedly declined to €9.2m (previous year €11.3m) • Revenues largely related to Carragelose product portfolio 3
Slide 7: Statement of profit or loss (IFRS)
Statement of profit or loss (IFRS) Higher revenues – increased R&D expenses 1 FY 2023 FY 2022 €m FY 2023 FY 2022 Sale of goods 8.1 10.5 Revenues 1 9.2 11.3 Cost of goods sold -5.8 -7.1 Margin 29.0% 32.3% Other income 2 1.4 0.8 Materials expenses -5.9 -7.3 •2 Primarily consisting of research premium
Slide 8: Statement of financial position (IFRS)
Statement of financial position (IFRS) Assets €m FY 2023 FY 2022 •1 Includes fully recognized headquarter, incl. land and Assets building (€5.3m), therein directly R&D related* (€0.4m) Intangible assets 1.5 1.8 2 Inventories €m FY 2023 FY 2022 Property, plant and equipment 1 5.9 6.2 Goods for sale 0
Slide 9: Statement of financial position (IFRS)
Statement of financial position (IFRS) Equity and liabilities €m FY 2023 FY 2022 •1 Primarily related to EIB loan (€10.0m) and ERP/aws and Equity and liabilities NÖBEG real estate refinancing (€4.6m) Share capital 1.5 1.5 Majority of accrued interest payable at maturity of loans. Capital reserves 44
Slide 10: Stabilized cash situation
Stabilized cash situation Low cash drain due to Carragelose revenues and inflows from convertible bond program • Ended December 2022 with €8.2m in cash (as a result of the €6.0m EIB tranche 3 draw down) • Raised +€0.5m through convertible note funding program • Earned +€3.2m net cash through profita
Slide 11: Deferral of EIB repayments by 18 months
Deferral of EIB repayments by 18 months Real estate lenders also agreed to suspension Tranche I Tranche II Tranche III EUR 4 million EUR 5 million EUR 4.7 million Outstanding nominal Outstanding nominal Outstanding nominal October 2024 → April 2026 December 2025 → June 2027 December 2025 - August 20
Slide 12: Agenda
Agenda • Highlights 2023 Andreas Grassauer, CEO • Financials 2023 Pascal Schmidt, CFO • Marinomed therapeutic areas, pipeline, Andreas Grassauer, CEO recent developments and next steps • New Carragelose data Eva Prieschl-Grassauer, CSO • Project status update & outlook Andreas Grassauer, CEO • Finan
Slide 13: Technologies & Therapeutic Areas
Technologies & Therapeutic Areas Universal blocking of viruses and allergens as well as Solubilization of poorly water-soluble compounds and moistening of mucosal tissues improving local onset of action Cough & cold Allergy Eye drops Budesolv Tacrosolv Solv4U portfolio* nasal spray* Dry, irritated A
Slide 14: Pipeline
Pipeline Including late-stage projects with low risk and meaningful upside potential Pharmaceutical Products Therapeutic Product Status Pre-clinical Phase I Phase II Phase III Filing Area Indication MAM-1004-1/Budesolv Filing in Treatment of severe allergic rhinitis preparation IMMUNOLOGY MAM-1003-1
Slide 15: Carragelose
Carragelose Universal blocking of viruses and allergens as well as moistening of mucosal tissues Recent developments • Expansion of product portfolio in Immunology with allergen blocker and eye drops • New distribution partnerships for Gulf region Without Carragelose: With Carragelose: and Eastern E
Slide 16: Carragelose: next steps
Carragelose: next steps Maximize value of Carragelose business • Completion of clinical study and launch of CHC market by category 2022* moisturizing Carragelose eye drops in Austria North America Western Europe • Drive BD process for allergy blocker and eye drops • Progress new partnerships e.g., i
Slide 17: Marinosolv
Marinosolv Solubilization of poorly water-soluble compounds - improving local onset of action Recent developments • MAM-1004-1/Budesolv • Innovation in formulation & primary packaging → improved stability • BD process gaining momentum Aqueous formulation of hardly Marinosolv formulation of • Partner
Slide 18: Marinosolv: next steps
Marinosolv: next steps Commercialization of lead assets & expanding Solv4U business Budesolv: • Add further partnerships in 2024 • Complete development towards marketing authorization with partners • Support partner Luoxin for China Tacrosolv: • Late-stage clinical development – enable near term par
Slide 19: Agenda
Agenda • Highlights 2023 Andreas Grassauer, CEO • Financials 2023 Pascal Schmidt, CFO • Marinomed therapeutic areas, pipeline, Andreas Grassauer, CEO recent developments and next steps • New Carragelose data Eva Prieschl-Grassauer, CSO • Project status update & outlook Andreas Grassauer, CEO • Finan
Slide 20: Carragelose acts as sustainable moisturizing agent
Carragelose acts as sustainable moisturizing agent In-vitro test to assess the hydrating potential of Carragelose on human cornea cells • Human cornea cells incubated for 2h Medium/Product mix is removed Cells are exposed to 33°C dry air. with medium containing • Carragelose • different marketed pro
Slide 21: Carragelose acts as sustainable moisturizing agent
Carragelose acts as sustainable moisturizing agent In-vitro test to assess the hydrating potential of Carragelose on human cornea cells • Human cornea cells incubated for 2h Percentage of cell survival following 10 minutes of with medium containing dehydration • Carragelose 100 • different marketed
Slide 22: Carragelose acts as sustainable moisturizing agent
Carragelose acts as sustainable moisturizing agent In-vitro test to assess the hydrating potential of Carragelose on human cornea cells • Human cornea cells were incubated for 2h with medium Positive Control: Negative Control: Carragelose-treated cells + containing Medium-treated cells 10 min dehydr
Slide 23: Carragelose acts as sustainable moisturizing agent
Carragelose acts as sustainable moisturizing agent Ex-vivo testing on porcine eyes to assess the hydrating potential of Carragelose • Eyes were treated every 15 min with 1 drop Fluorescin staining after 6h • NaCl 120 • Carragelose • a comparator marketed product 100 containing hyaluronic acid • Afte
Slide 24: Carragelose blocking properties
Carragelose blocking properties Barrier assay: Graphical representation For high-throughput: Incubation: Extraction: Readout: 96 deep well plate is used Allergens/Particles Via a buffer over night photometric wash step Barrier Agar • A deep well plate is filled with an agar block • Samples are added
Slide 25: Carragelose blocking properties
Carragelose blocking properties Carragelose functions as barrier against allergens and particles in-vitro Allergen-blocking properties Barrier function of • Blocking of allergen contact to mucosa tested in a surrogate Carragelose ophthalmic solution in-vitro test system 120% • In-vitro data generate
Slide 26: Agenda
Agenda • Highlights 2023 Andreas Grassauer, CEO • Financials 2023 Pascal Schmidt, CFO • Marinomed therapeutic areas, pipeline, Andreas Grassauer, CEO recent developments and next steps • New Carragelose data Eva Prieschl-Grassauer, CSO • Project status update & outlook Andreas Grassauer, CEO • Finan
Slide 27: Summary project status (April 2024)
Summary project status (April 2024) Project Status/next steps MAM-1003-1/Tacrosolv Late-stage clinical development - enable partnership in 2024 Immunology MAM-1004-1/Budesolv Additional partnerships in 2024; Work on registration with Luoxin for Greater China MAM-1001-4 nasal spray Launched in Austri
Slide 28: Translating innovation into top-line growth
Translating innovation into top-line growth Focus on reaching profitability target Maximize value of • Progress established partnerships (P&G, Vitaplus, Gaia, etc.) & fill white spots in Carragelose network • Launch/progress new Carragelose products (allergy blocker, eye drops) Carragelose business
Slide 29: Agenda
Agenda • Highlights 2023 Andreas Grassauer, CEO • Financials 2023 Pascal Schmidt, CFO • Marinomed therapeutic areas, pipeline, Andreas Grassauer, CEO recent developments and next steps • New Carragelose data Eva Prieschl-Grassauer, CSO • Project status update & outlook Andreas Grassauer, CEO • Finan
Slide 30: Financial calendar & IR contact
Financial calendar & IR contact Financial Calendar 2024 May 22, 2024 Publication of the Results Q1 2024 Record Date for participation June 10, 2024 at the Annual General Meeting June 20, 2024 7th Annual General Meeting August 20, 2024 Publication of the Results H1 2024 November 21, 2024 Publication
Slide 31: www.marinomed.com
www.marinomed.com 0) Marinomed